• Artiva Biotherapeutics posted a Q2 net loss of USD 25.01 million, widening from USD 21.25 million a year earlier.
• R&D spending rose to USD 21.93 million from USD 17.86 million, while G&A was little changed at USD 4.97 million.
• Cash, cash equivalents and investments climbed to USD 349.39 million at June 30 from USD 108.01 million at Dec. 31, 2025.
• FDA granted RMAT designation for AlloNK with rituximab in refractory rheumatoid arthritis; Phase 3 start planned in H2 2026 in about 150 patients.
• CEO Fred Aslan said EULAR data reinforced AlloNK’s potential for deep B-cell depletion with tolerability supportive of outpatient administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805015) on August 06, 2026, and is solely responsible for the information contained therein.